Gefitinib Long-term Survivor Study

Inclusion Criteria

• For inclusion in the long-term survivors group, the study subjects must fulfil the following criteria at the time of screening:
• 1. Provision of informed consent or EC approve informed consent waiver prior to any study specific procedures
• 2. Histological or cytological confirmed locally advanced NSCLC (stage III B) or metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy
• 3. EGFR mutation positive
• 4. Patients who continuously received gefitinib for at least 3 years without evidence of PD
• 5. Patients with OS ≥ 5 years from NSCLC diagnosis will be preferred
• 6. Collect archival tumour tissue before gefitinib treatment (blood and re-biopsy tumour tissue are optional); tumor tissue samples requirements: 1) slices requirements: >1 cm2, thickness 4-5 μm, ≥ 15 slices. or, whole FFPE block; 2) tumor percentage > 20% and necrosis < 30% by pathology QC.
• For inclusion in the rapid PD group, the study subjects must fulfil the following criteria:
• 1. Provision of informed consent or EC approve informed consent waiver prior to any study specific procedures
• 2. Histological or cytological confirmed locally advanced NSCLC (stage III B) or metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy
• 3. EGFR mutation positive
• 4. Patients who had undergone PD after gefitinib treatment≤3 months (Rapid PD)
• 5. Collect archival tumour tissue before gefitinib treatment (blood and re-biopsy tumour tissue samples are optional) ; tumor tissue samples requirements: 1) slices requirements: >1 cm2, thickness 4-5 μm, ≥ 15 slices. or, whole FFPE block; 2) tumor percentage > 20% and necrosis < 30% by pathology QC.